NOVEL MEDICAL USES OF 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1- ANTAGONISTIC ACTIVITY
    1.
    发明申请
    NOVEL MEDICAL USES OF 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1- ANTAGONISTIC ACTIVITY 审中-公开
    具有CB1-拮抗活性的4,5-二氢-1H-吡唑衍生物的新医学用途

    公开(公告)号:US20050239859A2

    公开(公告)日:2005-10-27

    申请号:US10929377

    申请日:2004-08-31

    IPC分类号: A61K31/415

    CPC分类号: A61K31/415

    摘要: Abstract of the DisclosureThe present invention relates to a novel medical use of 4,5-dihydro-1H-pyrazole compounds which are potent antagonists of the cannabis CB1-receptor. Said compounds are particularly suitable in the manufacture of medicaments for the treatment and/or prophylaxis of CB1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. The compounds have the general formula (I) wherein the group Bb represents sulfonyl or carbonyl, and the substituents R, R1, R2 and R3, and the group Aa are defined as shown in the description.

    摘要翻译: 本发明摘要本发明涉及作为大麻CB 1受体的有效拮抗剂的4,5-二氢-1H-吡唑化合物的新型医疗用途。 所述化合物特别适用于制备用于治疗和/或预防少年患者中CB 1受体相关疾病的药物和/或用于治疗和/或预防未成年人药物诱导的肥胖的药物 就像青少年患者一样。 化合物具有通式(I),其中基团Bb表示磺酰基或羰基,取代基R 1,R 1,R 2和R 3, SUB>,并且组Aa如说明书所示定义。

    Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
    2.
    发明申请
    Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds 审中-公开
    显示CB1拮抗活性的化合物的新型医疗用途和涉及所述化合物的组合治疗

    公开(公告)号:US20050124660A1

    公开(公告)日:2005-06-09

    申请号:US10969840

    申请日:2004-10-22

    摘要: The present invention relates to a novel medical use of compounds with CB1-receptor activity selected from the group of 4,5-dihydro-1H-pyrazole derivatives, 1H-Imidazole derivatives, thiazole derivatives and/or 1H-1,2,4-triazole-3-carboxamide derivatives, as each defined in the specification, or of a prodrug thereof, a tautomer thereof or a salt thereof, in the manufacture of medicaments for the treatment and/or prophylaxis of CB1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile, as well as in adolescent, patients. Furthermore, the invention pertains to the use of said compounds with CB1-receptor activity in combination with lipase inhibitors. Said compounds are particularly suitable in combination with lipase inhibitors in the manufacture of medicaments for the treatment and/or prophylaxis of obesity in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. Preferred lipase inhibitors are orlistat, panclicins, ATL-962 and/or lipstatin.

    摘要翻译: 本发明涉及一种具有选自4,5-二氢-1H-吡唑衍生物,1H-咪唑衍生物,噻唑衍生物和/或其中之一种具有CB 1 - 1 - 受体活性的化合物的新型医疗用途 在制备用于治疗和/或预防CB的药物中的1H-1,2,4-三唑-3-甲酰胺衍生物,如说明书中所定义,或其前药,其互变异构体或其盐 少年患者中的受体相关疾病和/或用于治疗和/或预防青少年以及青少年患者的药物诱导的肥胖症。 此外,本发明涉及具有CB 1/2受体活性的所述化合物与脂肪酶抑制剂的组合的用途。 所述化合物在制备用于治疗和/或预防青少年或青少年患者肥胖症的药物和/或用于治疗和/或预防青少年药物诱导的肥胖症以及 青少年患者。 优选的脂肪酶抑制剂是奥利司他,胰蛋白酶,ATL-962和/或脂抑素。

    Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
    3.
    发明申请
    Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity 审中-公开
    涉及具有CB1拮抗作用的4,5-二氢-1H-吡唑衍生物的肥胖症的新型医疗联合治疗

    公开(公告)号:US20050143441A1

    公开(公告)日:2005-06-30

    申请号:US11005486

    申请日:2004-12-07

    IPC分类号: A61K31/365 A61K31/4152

    摘要: The present invention relates to a novel medical use of e.g. 4,5-dihydro-1H-pyrazole compounds which are potent antagonists of the cannabis CB1-receptor in combination with lipase inhibitors. Said compounds are particularly suitable in combination with lipase inhibitors in the manufacture of medicaments for the treatment and/or prophylaxis of obesity in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. The compounds have the general formula (I) wherein the group Bb represents sulfonyl or carbonyl, and the substituents R, R1, R2 and R3, and the group Aa are defined as shown in the description. Preferred lipase inhibitors are orlistat, panclicins, ATL-962 and/or lipstatin.

    摘要翻译: 本发明涉及一种新的医疗用途。 4,5-二氢-1H-吡唑化合物,其是大麻CB 1 - 受体与脂肪酶抑制剂组合的有效拮抗剂。 所述化合物在制备用于治疗和/或预防青少年或青少年患者肥胖症的药物和/或用于治疗和/或预防青少年药物诱导的肥胖症以及 青少年患者。 化合物具有通式(I),其中基团Bb表示磺酰基或羰基,取代基R 1,R 1,R 2和R 3, SUB>,并且组Aa如说明书所示定义。 优选的脂肪酶抑制剂是奥利司他,胰蛋白酶,ATL-962和/或脂抑素。

    1 H-IMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS
    4.
    发明申请
    1 H-IMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS 失效
    1 H-咪唑衍生物作为CANNABINOID受体调节剂

    公开(公告)号:US20070281974A1

    公开(公告)日:2007-12-06

    申请号:US11842657

    申请日:2007-08-21

    CPC分类号: C07D233/90

    摘要: The invention relates to a group of 1H-imidazole derivatives which are modulators of cannabinoid receptors, to methods for the preparation of these compounds, to novel intermediates useful for the synthesis of said imidazole derivatives, to methods for the preparation of these intermediates, to pharmaceutical compositions containing one or more of these 1H-imidazole derivatives as active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of psychiatric and neurological disorders in which cannabinoid receptors are involved. The compounds have the general formula (I) wherein R, R1—R4 and X have the meanings given in the specification.

    摘要翻译: 本发明涉及一组作为大麻素受体的调节剂的1H-咪唑衍生物,制备这些化合物的方法,可用于合成所述咪唑衍生物的新中间体,制备这些中间体的方法,药物 含有这些1H-咪唑衍生物中的一种或多种作为活性成分的组合物,以及这些药物组合物用于治疗涉及大麻素受体的精神病和神经障碍的用途。 化合物具有通式(I),其中R 1,R 1 -R 4和X具有说明书中给出的含义。

    Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity
    6.
    发明申请
    Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity 有权
    四氮取代咪唑衍生物作为具有高CB1 / CB2受体亚型选择性的大麻素CB1受体调节剂

    公开(公告)号:US20050267161A1

    公开(公告)日:2005-12-01

    申请号:US11138289

    申请日:2005-05-27

    CPC分类号: C07D233/90

    摘要: The present invention relates to 1,2,4,5-tetrasubstituted imidazole derivatives as selective cannabinoid CB1 receptor modulators, in particular CB1 receptor antagonists or inverse agonists having a high CB1/CB2 receptor subtype selectivity, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said imidazole derivatives. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. A beneficial effect is disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. The invention also relates to the use of a compound of the invention for the manufacture of a medicament for treating or preventing a disease or condition. More particularly, the invention relates to a new use for the treatment of a disease or condition disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. In embodiments of the invention specific compounds disclosed herein are used for the manufacture of a medicament useful in the treatment of psychiatric and neurological disorders. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification.

    摘要翻译: 本发明涉及作为选择性大麻素CB 1受体调节剂的1,2,4,5-四取代的咪唑衍生物,特别是CB 1受体拮抗剂或具有高 CB 1 / CB 2受体亚型选择性,制备这些化合物的方法和可用于合成所述咪唑衍生物的新型中间体。 本发明还涉及本文公开的化合物在制备产生有益效果的药物中的用途。 本领域技术人员从本领域的说明书和一般知识中可以公开有益效果或显而易见的。 本发明还涉及本发明化合物在制备用于治疗或预防疾病或病症的药物中的用途。 更具体地,本发明涉及本领域技术人员从本领域技术人员的说明书和一般知识中治疗本文公开的疾病或病症的新用途。 在本发明的实施方案中,本文公开的具体化合物用于制备用于治疗精神病和神经障碍的药物。 化合物具有通式(I),其中符号具有说明书中给出的含义。

    Imidazoline derivatives having CB1-antagonistic activity
    7.
    发明申请
    Imidazoline derivatives having CB1-antagonistic activity 失效
    具有CB1拮抗活性的咪唑啉衍生物

    公开(公告)号:US20070135492A1

    公开(公告)日:2007-06-14

    申请号:US11652582

    申请日:2007-01-12

    CPC分类号: C07D233/26

    摘要: The present invention relates to 1,2,4-tri-substituted imidazoline derivatives, to methods for the preparation of these compounds, to novel intermediates useful for the synthesis of said imidazoline derivatives, to methods for the preparation of these intermediates, to pharmaceutical compositions containing one or more of these imidazoline derivatives as active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of psychiatric and neurological disorders. The compounds have the general formula. (I) wherein the symbols have the meanings given in the specification.

    摘要翻译: 本发明涉及1,2,4-三取代咪唑啉衍生物,制备这些化合物的方法,可用于合成所述咪唑啉衍生物的新中间体,制备这些中间体的方法,药物组合物 含有这些咪唑啉衍生物中的一种或多种作为活性成分,以及这些药物组合物用于治疗精神和神经障碍的用途。 该化合物具有通式。 (I)其中符号具有说明书中给出的含义。

    Imidazoline derivatives having CB1-antagonistic activity
    8.
    发明申请
    Imidazoline derivatives having CB1-antagonistic activity 有权
    具有CB1拮抗活性的咪唑啉衍生物

    公开(公告)号:US20050187259A1

    公开(公告)日:2005-08-25

    申请号:US11058168

    申请日:2005-02-16

    CPC分类号: C07D233/26

    摘要: The present invention relates to 1,2,4-tri-substituted imidazoline derivatives, to methods for the preparation of these compounds, to novel intermediates useful for the synthesis of said imidazoline derivatives, to methods for the preparation of these intermediates, to pharmaceutical compositions containing one or more of these imidazoline derivatives as active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of psychiatric and neurological disorders. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification.

    摘要翻译: 本发明涉及1,2,4-三取代咪唑啉衍生物,制备这些化合物的方法,可用于合成所述咪唑啉衍生物的新中间体,制备这些中间体的方法,药物组合物 含有这些咪唑啉衍生物中的一种或多种作为活性成分,以及这些药物组合物用于治疗精神病和神经障碍的用途。 化合物具有通式(I),其中符号具有说明书中给出的含义。

    1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
    10.
    发明申请
    1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity 有权
    具有CB1拮抗活性的1,3,5-三取代的4,5-二氢-1H-吡唑衍生物

    公开(公告)号:US20050171179A1

    公开(公告)日:2005-08-04

    申请号:US11033683

    申请日:2005-01-13

    IPC分类号: C07D231/06 A61K31/415

    CPC分类号: C07D231/06

    摘要: The present invention relates to 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives as CB1 antagonists, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said pyrazole derivatives. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification.

    摘要翻译: 本发明涉及作为CB 1拮抗剂的1,3,5-三取代的4,5-二氢-1H-吡唑衍生物,用于制备这些化合物的方法和用于合成的新中间体 的所述吡唑衍生物。 本发明还涉及本文公开的化合物在制备产生有益效果的药物中的用途。 化合物具有通式(I),其中符号具有说明书中给出的含义。